FDA clarifies that no drugs are approved to treat COVID-19 after Trump names 2 contenders


President Trump held up two drugs as possible treatments for COVID-19, the disease caused by the new coronavirus, in a conference call with governors on Thursday. He said chloroquine, an older drug used to treat malaria, lupus, and rheumatoid arthritis, was "very powerful" and has shown "very, very encouraging early results," adding that the Food and Drug Administration has approved the drug for use against the coronavirus.
The FDA said in a subsequent statement that "there are no FDA-approved therapeutics or drugs to treat, cure, or prevent COVID-19." Doctors can prescribe chloroquine "off-label," for unapproved uses, to treat COVID-19 patients.
Chloroquine, which can be lethal if taken by children or in large doses, will be tested in a "large, pragmatic clinical trial" with coronavirus patients, FDA Commissioner Stephen Hahn told reporters after Trump's briefing. German pharmaceutical giant Beyer said Thursday it is donating 3 million tablets of its chloroquine phosphate drug, Resochin, to the U.S. government for COVID-19 treatment research. Resochin is not currently approved for use in the U.S. Rising Pharmaceuticals, the only U.S. manufacturer of chloroquine, nearly doubled the drug's price on Jan. 23 — then restored the original price after an outcry, calling the price hike "coincidental," the Financial Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr. Ross McKinney Jr., chief scientific officer for the Association of American Medical Colleges, told reporters Thursday that while chloroquine may look promising in test tubes, he's "skeptical it will be effective" in COVID-19 patients. Infectious disease experts are more optimistic about the other treatment Trump mentioned, the experimental antiviral drug remdesivir from Gilead Sciences. Remdesivir is being tested in at least five experiments.
Researchers are also experimenting with HIV medications, several treatments for rheumatoid arthritis, and the Japanese flu medicine favipiravir, The Associated Press reports. "We're looking at drugs that are already approved for other indications" as stopgap treatments, Hahn said, but "we want to make sure this is done well and right."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Book reviews: ‘Red Scare: Blacklists, McCarthyism, and the Making of Modern America’ and ‘How to End a Story: Collected Diaries, 1978–1998’
Feature A political ‘witch hunt’ and Helen Garner’s journal entries
By The Week US Published
-
The backlash against ChatGPT's Studio Ghibli filter
The Explainer The studio's charming style has become part of a nebulous social media trend
By Theara Coleman, The Week US Published
-
Why are student loan borrowers falling behind on payments?
Today's Big Question Delinquencies surge as the Trump administration upends the program
By Joel Mathis, The Week US Published
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US Published
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
By Justin Klawans, The Week US Published
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
By Peter Weber, The Week US Published
-
What's Jeff Bezos' net worth?
In Depth The Amazon tycoon and third richest person in the world made his fortune pioneering online retail
By David Faris Published
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
By Peter Weber, The Week US Published
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
By Peter Weber, The Week US Published
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US Published
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US Published